These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 23497146)
1. Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing. Righi L; Cuccurullo A; Vatrano S; Cappia S; Giachino D; De Giuli P; Ardine M; Novello S; Volante M; Scagliotti GV; Papotti M BMC Cancer; 2013 Mar; 13():114. PubMed ID: 23497146 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients. Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094 [TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723 [TBL] [Abstract][Full Text] [Related]
4. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Ellison G; Zhu G; Moulis A; Dearden S; Speake G; McCormack R J Clin Pathol; 2013 Feb; 66(2):79-89. PubMed ID: 23172555 [TBL] [Abstract][Full Text] [Related]
5. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1). Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509 [TBL] [Abstract][Full Text] [Related]
6. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844 [TBL] [Abstract][Full Text] [Related]
7. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Passaro A; Prelaj A; Bonanno L; Tiseo M; Tuzi A; Proto C; Chiari R; Rocco D; Genova C; Sini C; Cortinovis D; Pilotto S; Landi L; Bennati C; Camerini A; Toschi L; Putzu C; Cerea G; Spitaleri G; Cappuzzo F; de Marinis F Clin Lung Cancer; 2019 Mar; 20(2):e186-e194. PubMed ID: 30563752 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647 [TBL] [Abstract][Full Text] [Related]
9. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325 [TBL] [Abstract][Full Text] [Related]
10. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. O'Donnell P; Ferguson J; Shyu J; Current R; Rehage T; Tsai J; Christensen M; Tran HB; Chien SS; Shieh F; Wei W; Lawrence HJ; Wu L; Schilling R; Bloom K; Maltzman W; Anderson S; Soviero S BMC Cancer; 2013 Apr; 13():210. PubMed ID: 23621958 [TBL] [Abstract][Full Text] [Related]
11. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes. Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122 [TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. Chung C J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240 [TBL] [Abstract][Full Text] [Related]
13. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Lozano MD; Zulueta JJ; Echeveste JI; Gúrpide A; Seijo LM; Martín-Algarra S; Del Barrio A; Pio R; Idoate MA; Labiano T; Perez-Gracia JL Oncologist; 2011; 16(6):877-85. PubMed ID: 21572125 [TBL] [Abstract][Full Text] [Related]
14. Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma. Namba K; Tomida S; Matsubara T; Takahashi Y; Kurihara E; Ogoshi Y; Yoshioka T; Takeda T; Torigoe H; Sato H; Shien K; Yamamoto H; Soh J; Tsukuda K; Toyooka S BMC Cancer; 2019 Feb; 19(1):175. PubMed ID: 30808329 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer. Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523 [TBL] [Abstract][Full Text] [Related]
16. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context". Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258 [TBL] [Abstract][Full Text] [Related]
18. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types]. Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541 [TBL] [Abstract][Full Text] [Related]
19. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups. Zhang Y; Wang Q; Han ZG; Shan L Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047 [TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays. Shen CI; Ho HL; Yeh YC; Chiu CH; Chou TY J Chin Med Assoc; 2020 Apr; 83(4):345-349. PubMed ID: 32101894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]